Mechanistically, JNK specifically phosphorylated c-Jun to increase the transcriptional activity of c-Jun, which recruited CBP/P300 to drive the transcription of CPT1A at the epigenetic level, followed by enhancement of FAO to induce tamoxifen resistance in ER-positive BC cells (Fig. 7h). The gene discussed is CPT1A; the disease is breast cancer.